1 / 16

Overcoming Barriers to TDM: Information and the TDM Renaissance

Overcoming Barriers to TDM: Information and the TDM Renaissance. How to integrate PK intelligence with routine clinical data. Alexander A. Vinks, PharmD, PhD, FCP Professor of Pediatrics, University of Cincinnati Director, TDM & Clinical PK Lab

mead
Télécharger la présentation

Overcoming Barriers to TDM: Information and the TDM Renaissance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Overcoming Barriers to TDM: Information and the TDM Renaissance How to integrate PK intelligence with routine clinical data Alexander A. Vinks, PharmD, PhD, FCP Professor of Pediatrics, University of Cincinnati Director, TDM & Clinical PK Lab Cincinnati Children’s Hospital and Medical Center

  2. “Therapeutic Drug Monitoring is the measurement made in the laboratory of a parameter which, with appropriate interpretation, will directly influence prescribing procedures” IFCC/IA-TDMCT Joint Committee 1993

  3. How should we do TDM? • Not to check numbers or “Therapeutic Range” • To describe and understand Drug PK/PD Behavior • Collect informative data to use as Bayesian priors for designing model-based, individualized dosing regimens • Change passive “Monitoring” to active “Management”

  4. The current paradigm Store and analyze data in our Heads, on Paper or in Computers BUT – where’s the link?

  5. Data base structure at CCHMC Clinical Lab KIDS COE CORE LCR NetAccess I yr Info Cerner Openlink Liver CF SQL ADT Neuro

  6. Goal oriented - model based dosing

  7. Running a centralized TDM service

  8. Specific Objectives TDM Study • Implementation of Active Therapeutic Monitoring (ATM): • goal-oriented model-based dosing • active guidance and Bayesian adaptive control vs non-guided TDM • Outcomes - clinical and economical benefits • Cost evaluation of old and new TDM process

  9. Distribution of Peaks & Troughs

  10. Kaplan-Meier survival analysis TDM cost-effectiveness study; van Lent-Evers et al. Ther Drug Monit 1999;21:63-73

  11. Active Therapeutic Monitoring benefits patient outcome TDM cost-effectiveness study; van Lent-Evers et al. Ther Drug Monit 1999;21:63-73

  12. Development of Web-based tools

  13. Web-based data collection tools

  14. Dates and timing of samples • Daily measurements • Early morning troughs • But also other times! • Interpretation?

  15. Liver transplant case history • 10 yr old African American boy • Transplant 1998 • Rejection July 1998 & December 2000 • FK levels <1.5 µg/L at 4 mg bid • Fluctuating levels between 1.5-5 µg/L Q: Compliance – high clearance – other?

  16. Conclusions… • TDM informatics is still in its infancy • Passive monitoring should be replaced by active Management • Need better tools to link all clinical data to drug behavior (PK) data • Data base should link patient info with Population PK, Pharmacogenetics (PG), Adverse Events and Clinical Effects (PD) data

More Related